Matches in SemOpenAlex for { <https://semopenalex.org/work/W2759969754> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2759969754 endingPage "17" @default.
- W2759969754 startingPage "16" @default.
- W2759969754 abstract "Treatment decision making in prostate cancer (PCa) is increasingly complex. Especially with numerous immunologic, chemotherapeutic, radiopharmaceutical, and hormonal treatment options approved by the Food and Drug Administration over the past few years, which makes issues of balancing treatment benefit, harms, and values difficult to assess. 1 D'Amico A.V. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol. 2014; 32: 362-364 Crossref PubMed Scopus (30) Google Scholar Castrate-resistant PCa can be treated with immunotherapy (sipuleucel-T), which involves genetically engineering immune cells, hormone therapy (abiraterone and enzalutamide), radiopharmaceuticals (radium-223), or chemotherapy (docetaxel or cabazitaxel). 2 National Comprehensive Cancer Network Prostate Cancer NCCN Evidence BlocksTM. National Comprehensive Cancer Network, 2016https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdfDate accessed: May 5, 2017 Google Scholar Although the National Comprehensive Cancer Network provides guidance on therapeutic selection and even some therapy sequence (especially postdocetaxel), many issues surround metastatic castrate-resistant prostate cancer therapy options, and clinicians disagree on which drug is best for which patient. In addition, other important factors are hotly debated, such as the best time to start and stop various therapies. 3 American Cancer Society Treating Prostate Cancer—Hormone Therapy for Prostate Cancer. American Cancer Society, Atlanta2017www.cancer.org http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-treating-hormone-therapyDate accessed: May 5, 2017 Google Scholar The lack of comparative studies for life-prolonging agents is problematic, as is the lack of testing sequential therapies (especially after abiraterone and enzalutamide)." @default.
- W2759969754 created "2017-10-06" @default.
- W2759969754 creator A5037456539 @default.
- W2759969754 creator A5073246821 @default.
- W2759969754 creator A5081267338 @default.
- W2759969754 date "2017-11-01" @default.
- W2759969754 modified "2023-09-23" @default.
- W2759969754 title "Editorial Comment" @default.
- W2759969754 cites W2095283907 @default.
- W2759969754 cites W2235405584 @default.
- W2759969754 cites W2991792334 @default.
- W2759969754 doi "https://doi.org/10.1016/j.urology.2017.04.063" @default.
- W2759969754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28941944" @default.
- W2759969754 hasPublicationYear "2017" @default.
- W2759969754 type Work @default.
- W2759969754 sameAs 2759969754 @default.
- W2759969754 citedByCount "0" @default.
- W2759969754 crossrefType "journal-article" @default.
- W2759969754 hasAuthorship W2759969754A5037456539 @default.
- W2759969754 hasAuthorship W2759969754A5073246821 @default.
- W2759969754 hasAuthorship W2759969754A5081267338 @default.
- W2759969754 hasConcept C121608353 @default.
- W2759969754 hasConcept C126322002 @default.
- W2759969754 hasConcept C143998085 @default.
- W2759969754 hasConcept C2776551883 @default.
- W2759969754 hasConcept C2777701055 @default.
- W2759969754 hasConcept C2777899217 @default.
- W2759969754 hasConcept C2778971682 @default.
- W2759969754 hasConcept C2780192828 @default.
- W2759969754 hasConcept C2781190966 @default.
- W2759969754 hasConcept C61367390 @default.
- W2759969754 hasConcept C71924100 @default.
- W2759969754 hasConceptScore W2759969754C121608353 @default.
- W2759969754 hasConceptScore W2759969754C126322002 @default.
- W2759969754 hasConceptScore W2759969754C143998085 @default.
- W2759969754 hasConceptScore W2759969754C2776551883 @default.
- W2759969754 hasConceptScore W2759969754C2777701055 @default.
- W2759969754 hasConceptScore W2759969754C2777899217 @default.
- W2759969754 hasConceptScore W2759969754C2778971682 @default.
- W2759969754 hasConceptScore W2759969754C2780192828 @default.
- W2759969754 hasConceptScore W2759969754C2781190966 @default.
- W2759969754 hasConceptScore W2759969754C61367390 @default.
- W2759969754 hasConceptScore W2759969754C71924100 @default.
- W2759969754 hasLocation W27599697541 @default.
- W2759969754 hasLocation W27599697542 @default.
- W2759969754 hasOpenAccess W2759969754 @default.
- W2759969754 hasPrimaryLocation W27599697541 @default.
- W2759969754 hasRelatedWork W122177069 @default.
- W2759969754 hasRelatedWork W1652439388 @default.
- W2759969754 hasRelatedWork W179251896 @default.
- W2759969754 hasRelatedWork W2015876133 @default.
- W2759969754 hasRelatedWork W2021751111 @default.
- W2759969754 hasRelatedWork W2135620818 @default.
- W2759969754 hasRelatedWork W2568045406 @default.
- W2759969754 hasRelatedWork W2768688864 @default.
- W2759969754 hasRelatedWork W3132581442 @default.
- W2759969754 hasRelatedWork W4291017293 @default.
- W2759969754 hasVolume "109" @default.
- W2759969754 isParatext "false" @default.
- W2759969754 isRetracted "false" @default.
- W2759969754 magId "2759969754" @default.
- W2759969754 workType "editorial" @default.